EyeGate Pharmaceuticals, Inc.
271 Waverley Oaks Road, Suite 108
Waltham, Massachusetts 02452
|
April 10, 2018
VIA EDGAR
United States Securities and Exchange Commission |
| Re: | EyeGate Pharmaceuticals, Inc. (the “Company”) |
Registration Statement on Form S-1
File No. 333-223887
Request for Acceleration
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the Registration Statement on Form S-1 (File No. 333-223887) (the “Registration Statement”) of the Company. The Company respectfully requests that the Registration Statement become effective as of 5:15 p.m., Washington, D.C. time, on April 12, 2018, or as soon as practicable thereafter.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Robert A. Petitt of Burns & Levinson LLP at (617) 345-3361 and that such effectiveness also be confirmed in writing.
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (781) 788-9043 or our attorney, Robert A. Petitt at the number above. Thank you for your assistance.
|
Very truly yours,
EyeGate Pharmaceuticals, Inc.
By: /s/ Stephen From Name: Stephen From Title: President and Chief Executive Officer | |
| cc: | Robert A. Petitt, Esq., Burns & Levinson LLP |